Marché mondial de la maladie de Dupuytren – Tendances et prévisions du secteur jusqu'en 2030

Analyse et taille du marché de la maladie de Dupuytren :

La prévalence croissante est l'un des principaux facteurs de croissance du marché mondial de la maladie de Dupuytren. Les progrès de la technologie médicale et l'augmentation des dépenses en infrastructures de soins de santé accélèrent la croissance du marché mondial de la maladie de Dupuytren. La prévalence croissante de la maladie entraîne une croissance considérable du marché. Selon une étude récente publiée dans le Journal of Hand Surgery, on constate une augmentation significative des cas diagnostiqués, ce qui indique qu'une plus grande population de patients a besoin d'alternatives de traitement. En conséquence, les sociétés pharmaceutiques et les fabricants de dispositifs médicaux ont augmenté leurs dépenses en recherche et développement pour répondre à la demande de meilleures techniques de gestion. En outre, une étude de population réalisée en 2021 aux États-Unis a révélé que jusqu'à 7 % de la population présentait des symptômes cliniques, plus d'un tiers de ce groupe étant touché par l'impact des contractures de Dupuytren sur les fonctions quotidiennes.

Français Data Bridge Market Research analyse que le marché mondial de la maladie de Dupuytren, qui était de 39,8 milliards USD en 2022, devrait atteindre 145,7 milliards USD d'ici 2030 et devrait connaître un TCAC de 22,20 % au cours de la période de prévision de 2023 à 2030. Le segment « Chirurgie, radiothérapie » domine le segment de traitement du marché mondial de la maladie de Dupuytren en raison des progrès technologiques qui ont conduit au développement de produits pharmaceutiques à usages divers. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également des analyses approfondies d'experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la maladie de Dupuytren

Market Definition

Dupuytren's disease, also known as dupuytren's contracture, is a progressive condition that affects the hand and fingers. It is characterized by the thickening and tightening of the connective tissue called the palmar fascia, which lies beneath the skin of the palm and fingers. This fibrous tissue forms nodules and cords that can gradually contract, leading to the curling and bending of the affected fingers towards the palm.

Global Dupuytren’s Disease Market dynamics

Drivers

• Increasing Prevalence

The prevalence of dupuytren's disease is rising globally, particularly in aging populations. Factors such as genetics, gender, and certain lifestyle choices contribute to its development. The growing number of affected individuals creates a significant market demand for effective treatments

• Advancements in Diagnostic Techniques:

Improvements in diagnostic techniques, including imaging technologies and biomarker identification, have facilitated early and accurate detection of dupuytren's disease. Early diagnosis allows for timely intervention and treatment, driving the demand for effective therapies.

• Technological Advancements in Treatment Options

The field of dupuytren's disease treatment has witnessed technological advancements, leading to the development of novel and minimally invasive treatment options. Procedures such as needle aponeurotomy, collagenase injection, and radiotherapy have gained popularity, offering alternatives to traditional surgical approaches. These advancements provide patients with more treatment choices, driving market growth.

Opportunities

• Growing Patient Awareness

Increasing awareness about dupuytren's disease among patients, healthcare professionals, and the general population has contributed to the diagnosis and treatment-seeking behaviour Educational initiatives, patient support groups, and online resources have played a crucial role in enhancing awareness and driving market growth

• Rising Demand for Non-Surgical Interventions

Many patients prefer non-surgical interventions that are less invasive, have shorter recovery times, and offer comparable outcomes to traditional surgical procedures. The development of non-surgical treatments such as injectable collagenase has gained traction and is expected to drive market growth.

Restraints/Challenges

• Lack of Awareness

One of the significant challenges is the limited awareness and understanding of Dupuytren's disease among the general population and even some healthcare professionals. This can lead to delays in diagnosis and treatment, as well as underreporting of the condition.

• Misdiagnosis and Underdiagnosis

Dupuytren's disease can often be misdiagnosed or overlooked, especially in its early stages. Its symptoms, such as nodules or thickened cords in the palm, can be mistaken for other conditions or considered insignificant. This can result in delayed intervention and progression of the disease.

This global dupuytren’s disease market   report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dupuytren’s disease market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO, AJOVY, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business
• In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd.

Global Dupuytren’s Disease Market scope

The global dupuytren’s disease market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Treatment

• Surgery
• Radiation Therapy
• Needle Aponeurotomy
• Steroid Shot
• Enzyme Injection
• Occupational Therapy
• Others

 Diagnosis

• Physical Examination
• X-Ray
• Others

 Dosage

• Injection
• Tablets
• Others

 Route of Administration

• Oral
• Parenteral
• Others

 End Users

• Clinic
• Hospital
• Others

Global Dupuytren’s Disease Market Regional Analysis/Insights

The global dupuytren’s disease market    is analysed and market size insights and trends are the basis treatment, diagnosis, dosage, route of administration, end users as referenced above.

The countries covered in the global dupuytren’s disease market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa

North America dominates the global dupuytren’s disease market due to the presence of major key players, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region.

Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Dupuytren’s Disease Market Share Analysis

Le paysage concurrentiel du marché mondial de la maladie de Dupuytren fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial de la maladie de Dupuytren.

Certains des principaux acteurs opérant sur le marché mondial de la maladie de Dupuytren sont :

• Merck & Co., Inc. (États-Unis)
• Fresenius Kabi AG (Allemagne)
•  Société Bristol-Myers Squibb (États-Unis)
• Endo International plc (Irlande)
• Pfizer Inc. (États-Unis)
• Hikma Pharmaceuticals PLC (États-Unis)
• Spear Pharmaceuticals. (États-Unis)
• Actiza Pharmaceutical Private Limited (Inde)
• Nantong Jinghua Pharmaceutical Co., Ltd. (États-Unis)
• GSK plc (États-Unis)
• Abbott (États-Unis)
• Bayer AG (États-Unis)
• AstraZeneca (États-Unis)
• Johnson & Johnson Services Ltd. (États-Unis)
• Cipla Inc. (États-Unis)
• LEO Pharma A/S (États-Unis)
• Sumitomo Dainippon Pharma Co., Ltd. (Japon)
• Novartis AG (États-Unis)
• Sanofi (France)
• Aurobindo Pharma (Inde)
• Lupin (Inde)

SKU-67819